Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,767 | -25,745 | -18,212 | -12,221 | -6,157 |
| Depreciation Amortization | 47 | 172 | 117 | 79 | 37 |
| Accounts receivable | -9 | -101 | 81 | 31 | 17 |
| Other Working Capital | -707 | -6,765 | -7,333 | -2,594 | 250 |
| Other Operating Activity | 1,434 | 2,444 | 1,325 | 872 | -285 |
| Operating Cash Flow | $-6,003 | $-29,995 | $-24,022 | $-13,833 | $-6,137 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -169 | -75 | -31 | 11 | -7 |
| Investing Cash Flow | $-169 | $-75 | $-31 | $11 | $-7 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -9,075 | -9,075 | -4,495 | N/A |
| Common Stock Issued | 430 | 363 | 337 | 337 | 337 |
| Other Financing Activity | 0 | 54,496 | 22,791 | 22,812 | 22,833 |
| Financing Cash Flow | $430 | $45,784 | $14,053 | $18,654 | $23,170 |
| Exchange Rate Effect | 96 | -1,955 | -680 | -858 | -461 |
| Beginning Cash Position | 33,101 | 19,342 | 19,342 | 19,342 | 19,342 |
| End Cash Position | 27,455 | 33,101 | 8,662 | 23,316 | 35,908 |
| Net Cash Flow | $-5,647 | $13,760 | $-10,680 | $3,974 | $16,566 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,003 | -29,995 | -24,022 | -13,833 | -6,137 |
| Capital Expenditure | -169 | -104 | -60 | -18 | -7 |
| Free Cash Flow | -6,172 | -30,099 | -24,082 | -13,850 | -6,144 |